Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States. (15th August 2022)

• Record Type: Journal Article
• Authors: Gomez, Gabriela B; Nelson, Christopher B; Rizzo, Christopher; Shepard, Donald S; Chaves, Sandra S
• Is Part Of: Journal of infectious diseases. Volume 226(2022)Supplement 2
• Page Start: S293
• Page End: S299
• Publication Date: 2022-08-15
• Subjects: infants -- insurance -- United States -- respiratory syncytial virus infections -- lower respiratory tract infections -- health care utilization -- equity -- model; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac164
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: The target populations and financing mechanisms for a new health technology may affect health inequalities in access and impact. We projected the distributional consequences of introducing nirsevimab for prevention of respiratory syncytial virus in a US birth cohort of infants through alternative reimbursement pathway scenarios. Using the RSV immunization impact model, we estimated that a vaccine-like reimbursement pathway would cover 32% more infants than a pharmaceutical pathway. The vaccine pathway would avert 30% more hospitalizations and 39% more emergency room visits overall, and 44% and 44%, respectively, in publicly insured infants. The vaccine pathway would benefit infants from poorer households.